Skip to main content

Entera Bio Ltd.

corporate_fare Company Profile

Entera Bio Ltd.

ENTX·NASDAQ·Life Sciences·CIK 0001638097

Entera is a clinical stage company focused on developing oral tablet forms of peptide or protein replacement therapies for chronic medical conditions. The company aims to address underserved conditions where oral administration of protein therapy could significantly change treatment. Most protein therapies are currently given through frequent intravenous, subcutaneous, or intramuscular injections, which can be challenging for patients with chronic diseases. Entera's pipeline includes oral peptides targeting PTH(1-34), GLP-1/Glucagon, and GLP-2. The company uses its N-Tab® platform, designed to stabilize large (4kD+) hydrophilic peptides in the gastrointestinal tract and promote their absorption into the bloodstream. The most advanced product candidate is EB613 (oral teriparatide, or oral PTH[1-34]), which is being developed as the first oral, osteoanabolic (bone building) tablet treatment for osteoporosis. EB613 is being developed under a 505(b)(2) application, referencing Forteo® (teriparatide SC injection, Eli Lilly). Forteo® was initially approved by the FDA in 2002 for postmenopausal women with osteoporosis at high risk of fracture, and later for men with osteoporosis and osteoporosis associated with sustained systemic glucocorticoid therapy. Forteo® has been in clinical use for over 20 years. Osteoporosis is a chronic disorder where bone resorption exceeds formation, leading to decreased bone strength and increased fracture susceptibility. It causes over two million fractures annually in the United States. After age 50, one in three women and one in five men will experience an osteoporosis-related fracture. Studies indicate that up to 20-24% of hip fracture patients die within one year.

Entera Bio Ltd. (NASDAQ:ENTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 30 items for ENTX at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Entera Bio Secures $10M Private Placement from BVF Partners to Fund Phase 3 Study, Addressing Going Concern
  • Entera Bio Secures $10M Direct Investment from BVF Partners, Potentially $24.5M Total
  • Entera Bio's Fiscal 2025 10-K Shows $0.042M Revenue, $0.25 Loss Per Share
  • Entera Bio Reports Substantial Doubt on Going Concern, Critical Funding Needed for Lead Program
  • Entera Bio Details Accelerated EB613 Phase 3 & FDA Alignment Amidst Short Cash Runway

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$42K
Net Income
-$11.44M
Diluted EPS
$0.25
Op. Cash Flow
-$7.37M
Free Cash Flow
-$7.48M
Gross Profit
$0
Operating Income
-$11.53M
Cash & Equivalents
$7.11M
Debt / Equity
0.00×
Net Margin
-272.36×
Shares Outstanding
46.18M sh
Source: 10-K · filed 2026-03-27 · accession 0001178913-26-001797
$3.3 -0.15% today
52-week range · as of 2026-10-14 $0.91 – $4.2
Market cap
$575.53M
Volume
469.1K (1.2× avg)
3-mo avg 401.9K
Live data · 2026-11-22 03:31 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ENTX - Filings & News (Page 2)

ENTX
Apr 03, 2026, 4:15 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.24
Real-time Price: $3.30 info
Change: +$2.06 (+166%) info
Market Cap: $575.525M info
ENTX
Apr 02, 2026, 8:45 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $1.21
Real-time Price: $3.30 info
Change: +$2.09 (+173%) info
Market Cap: $575.525M info
ENTX
Mar 27, 2026, 4:25 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.18
Real-time Price: $3.30 info
Change: +$2.12 (+180%) info
Market Cap: $575.525M info
ENTX
Mar 27, 2026, 4:20 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $1.18
Real-time Price: $3.30 info
Change: +$2.12 (+180%) info
Market Cap: $575.525M info
ENTX
Mar 27, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.18
Real-time Price: $3.30 info
Change: +$2.12 (+180%) info
Market Cap: $575.525M info
ENTX
Mar 27, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.13
Real-time Price: $3.30 info
Change: +$2.17 (+192%) info
Market Cap: $575.525M info
ENTX
Mar 23, 2026, 8:56 AM EDT
Source: FinanceWire
Importance Score:
9
Price at Filing: $1.21
Real-time Price: $3.30 info
Change: +$2.09 (+173%) info
Market Cap: $575.525M info
ENTX
Mar 04, 2026, 9:00 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.39
Real-time Price: $3.30 info
Change: +$1.91 (+137%) info
Market Cap: $575.525M info
ENTX
Feb 09, 2026, 8:46 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.08
Real-time Price: $3.30 info
Change: +$2.22 (+206%) info
Market Cap: $575.525M info
ENTX
Feb 04, 2026, 8:00 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.18
Real-time Price: $3.30 info
Change: +$2.12 (+180%) info
Market Cap: $575.525M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets